Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- University of California, Berkeley
- Target Recruit Count
- 40
- Registration Number
- NCT06367738
The Impact of Psilocybin on Pain in Fibromyalgia Patients
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Maastricht University
- Target Recruit Count
- 35
- Registration Number
- NCT06368492
- Locations
- π³π±
Maastricht University, Maastricht, Limburg, Netherlands
π³π±Leiden University Medical Center, Leiden, South Holland, Netherlands
Psilocybin in Chronic Low Back Pain and Depression
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 40
- Registration Number
- NCT06355414
- Locations
- πΊπΈ
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD
- Conditions
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 200
- Registration Number
- NCT06349083
- Locations
- πΊπΈ
NYU Langone Health, New York, New York, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- MycoMedica Life Sciences PBC
- Target Recruit Count
- 24
- Registration Number
- NCT06326606
- Locations
- π¦πΊ
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 20
- Registration Number
- NCT06303739
- Locations
- πΊπΈ
UNC Chapel Hill Medical Center, Chapel Hill, North Carolina, United States
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 10
- Registration Number
- NCT06299319
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Sharmin Ghaznavi
- Target Recruit Count
- 20
- Registration Number
- NCT06247839
- Locations
- πΊπΈ
Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, United States
Mindfulness-assisted Psychedelic Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 40
- Registration Number
- NCT06233344
- Locations
- πΊπΈ
Univeristy of Southern California Brain and Creativity Institute, Los Angeles, California, United States
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06200155
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.